Update date
31 Dec 2025
Shareable Research Card
TLX - Telix Pharmaceuticals Ltd Interest Expense
This metric view shows TLX - Telix Pharmaceuticals Ltd interest expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2025
- Latest reported value
- $181,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2025.
- Latest reported value on this page: $181,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Interest Expense
Latest reported interest expense: $181,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2025
SEC-backed company facts were refreshed from filings filed on 20 Feb 2026.
Benchmark Context
How Interest Expense compares with peers
Telix Pharmaceuticals Ltd is outside the visible top 120 companies for interest expense in the current sample.
Compared with
Compared with 120 companies reporting interest expense in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Interest Expense is up about 183% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2017 to 31 Dec 2025.
- Nearby companies in this sample: HSBC HOLDINGS PLC and KB Financial Group Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Telix Pharmaceuticals Ltd: Interest Expense
Latest period: 2025. Period end: 31 Dec 2025. Units: USD and AUD. Frequency: annual.
Interest Expense is an SEC-reported metric from company XBRL facts.
Metric Snapshot
- Latest value
- $181,000
- Coverage range
- 31 Dec 2022 - 31 Dec 2025
- Fact rows
- 6
What This Metric Tells You
- Shows the reported level of interest expense over 31 Dec 2022 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 6 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Interest Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | HSBC HOLDINGS PLC (hsbc) | $63,078,000,000 | Year - 31 Dec 2025 | Open HSBC HOLDINGS PLC Interest Expense |
| 2 | KB Financial Group Inc. (kb) | $11,952,871,000 | Year - 31 Dec 2024 | Open KB Financial Group Inc. Interest Expense |
| 3 | BROOKFIELD Corp /ON/ (bn) | $10,702,000,000 | Year - 31 Dec 2022 | Open BROOKFIELD Corp /ON/ Interest Expense |
| 4 | WOORI FINANCIAL GROUP INC. (wf) | $8,881,600,000 | Year - 31 Dec 2024 | Open WOORI FINANCIAL GROUP INC. Interest Expense |
| 5 | Shell plc (shel) | $4,671,000,000 | Year - 31 Dec 2025 | Open Shell plc Interest Expense |
| 6 | Brookfield Infrastructure Partners L.P. (bip) | $3,868,000,000 | Year - 31 Dec 2025 | Open Brookfield Infrastructure Partners L.P. Interest Expense |
Metric Details
- Metric
- Interest Expense (InterestExpense)
- Taxonomy
- ifrs-full
- Units tracked
- USD and AUD
- Frequency coverage
- annual
- History range
- 31 Dec 2022 - 31 Dec 2025
- Facts on this page
- 6
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Interest Expense, Annual (USD)
Interest Expense, YoY Annual Change (%)
Interest Expense, Annual (AUD)
Interest Expense, YoY Annual Change (%)
Telix Pharmaceuticals Ltd Annual Interest Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $181,000 | +$117,000 | +183% | 01 Jan 2025 | 31 Dec 2025 | 20-F | 20 Feb 2026 | 2025 | FY |
| 2024 | $64,000 | -$33,000 | -34% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 20 Feb 2026 | 2025 | FY |
| 2023 | $97,000 | 01 Jan 2023 | 31 Dec 2023 | 20-F | 20 Feb 2026 | 2025 | FY |
Telix Pharmaceuticals Ltd Annual Interest Expense (AUD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | A$82,000 | -A$66,000 | -45% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 24 Feb 2025 | 2024 | FY |
| 2023 | A$148,000 | +A$102,000 | +222% | 01 Jan 2023 | 31 Dec 2023 | 20-F | 24 Feb 2025 | 2024 | FY |
| 2022 | A$46,000 | 01 Jan 2022 | 31 Dec 2022 | 20-F | 24 Feb 2025 | 2024 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.